Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts.

Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Schärer OD, Grollman AP.

Nucleic Acids Res. 2012 Mar;40(6):2494-505. doi: 10.1093/nar/gkr1095. Epub 2011 Nov 25.

2.

Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adducts.

Lukin M, Zaliznyak T, Johnson F, de los Santos C.

Nucleic Acids Res. 2012 Mar;40(6):2759-70. doi: 10.1093/nar/gkr1094. Epub 2011 Nov 25.

3.

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG.

Kidney Int. 2012 Mar;81(6):559-67. doi: 10.1038/ki.2011.371. Epub 2011 Nov 9.

4.

Aristolochic acids.

National Toxicology Program.

Rep Carcinog. 2011;12:45-9. No abstract available.

5.

TP53 Mutational signature for aristolochic acid: an environmental carcinogen.

Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelaković B, Wu L, Truong S, Fernandes A, Grollman AP.

Int J Cancer. 2011 Sep 15;129(6):1532-6. doi: 10.1002/ijc.26077. Epub 2011 Jun 9.

6.

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC.

PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821.

7.

Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study.

Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD.

Am J Kidney Dis. 2010 Mar;55(3):507-18. doi: 10.1053/j.ajkd.2009.10.055. Epub 2010 Feb 8.

PMID:
20116155
8.

Arsenic in drinking water and risk of urinary tract cancer: a follow-up study from northeastern Taiwan.

Chen CL, Chiou HY, Hsu LI, Hsueh YM, Wu MM, Wang YH, Chen CJ.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):101-10. doi: 10.1158/1055-9965.EPI-09-0333.

9.

Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.

Lai MN, Wang SM, Chen PC, Chen YY, Wang JD.

J Natl Cancer Inst. 2010 Feb 3;102(3):179-86. doi: 10.1093/jnci/djp467. Epub 2009 Dec 21.

10.

DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells.

Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR, Johnson F.

Nucleic Acids Res. 2010 Jan;38(1):339-52. doi: 10.1093/nar/gkp815. Epub 2009 Oct 23.

11.

Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract.

Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, Rouprêt M.

BJU Int. 2009 Nov;104(10):1436-40. doi: 10.1111/j.1464-410X.2009.08838.x. Epub 2009 Aug 18. Review.

12.

TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.

Nedelko T, Arlt VM, Phillips DH, Hollstein M.

Int J Cancer. 2009 Feb 15;124(4):987-90. doi: 10.1002/ijc.24006.

13.
14.

Cellular mechanisms of tumour suppression by the retinoblastoma gene.

Burkhart DL, Sage J.

Nat Rev Cancer. 2008 Sep;8(9):671-82. doi: 10.1038/nrc2399. Review.

PMID:
18650841
15.

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW.

Eur Urol. 2009 Mar;55(3):650-7. doi: 10.1016/j.eururo.2008.06.013. Epub 2008 Jun 13.

PMID:
18584939
16.

Aristolochic acid nephropathy: a worldwide problem.

Debelle FD, Vanherweghem JL, Nortier JL.

Kidney Int. 2008 Jul;74(2):158-69. doi: 10.1038/ki.2008.129. Epub 2008 Apr 16. Review.

17.

Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease.

Chen CY, Liao YM, Tsai WM, Kuo HC.

J Formos Med Assoc. 2007 Dec;106(12):992-8. doi: 10.1016/S0929-6646(08)60074-1.

18.

p53 and retinoblastoma pathways in bladder cancer.

Mitra AP, Birkhahn M, Cote RJ.

World J Urol. 2007 Dec;25(6):563-71. Epub 2007 Aug 21. Review.

PMID:
17710407
19.

Aristolochic acid and the etiology of endemic (Balkan) nephropathy.

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12129-34. Epub 2007 Jul 9.

20.

Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market.

Martena MJ, van der Wielen JC, van de Laak LF, Konings EJ, de Groot HN, Rietjens IM.

Anal Bioanal Chem. 2007 Sep;389(1):263-75. Epub 2007 May 8.

PMID:
17486320

Supplemental Content

Support Center